ProfileGDS4814 / ILMN_1776105
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 79% 78% 81% 80% 78% 82% 76% 80% 75% 79% 80% 78% 82% 76% 81% 84% 79% 80% 80% 79% 78% 79% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)137.59379
GSM780708Untreated after 4 days (C2_1)126.81278
GSM780709Untreated after 4 days (C3_1)155.79281
GSM780719Untreated after 4 days (C1_2)143.81680
GSM780720Untreated after 4 days (C2_2)120.08978
GSM780721Untreated after 4 days (C3_2)177.77982
GSM780710Trastuzumab treated after 4 days (T1_1)107.90376
GSM780711Trastuzumab treated after 4 days (T2_1)141.19280
GSM780712Trastuzumab treated after 4 days (T3_1)99.725275
GSM780722Trastuzumab treated after 4 days (T1_2)128.20279
GSM780723Trastuzumab treated after 4 days (T2_2)139.21880
GSM780724Trastuzumab treated after 4 days (T3_2)120.41878
GSM780713Pertuzumab treated after 4 days (P1_1)174.81682
GSM780714Pertuzumab treated after 4 days (P2_1)103.55776
GSM780715Pertuzumab treated after 4 days (P3_1)153.05981
GSM780725Pertuzumab treated after 4 days (P1_2)216.13784
GSM780726Pertuzumab treated after 4 days (P2_2)135.88879
GSM780727Pertuzumab treated after 4 days (P3_2)149.20180
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)139.63180
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)130.43879
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)125.93478
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)131.02779
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)137.60979